LON:PRM

Proteome Sciences Interim Earnings Results & Report

Proteome Sciences logo
GBX 1.04 -0.13 (-11.11%)
As of 11/20/2026 12:40 PM Eastern

Proteome Sciences reported Interim earnings on September 16, 2026. The company reported EPS of -GBX 0.41.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

Proteome Sciences EPS Results

Actual EPS
-GBX 0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Proteome Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Proteome Sciences Interim Earnings FAQ

Proteome Sciences (LON:PRM) reported earnings of -GBX 0.41 per share for Interim. The report was announced on Wednesday, September 16, 2026.

Proteome Sciences Earnings Headlines

PRM.L - | Stock Price & Latest News | Reuters
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Proteome Sciences H1 Loss Narrows
See More Proteome Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Proteome Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Proteome Sciences and other key companies, straight to your email.

About Proteome Sciences

Proteome Sciences (LON:PRM) provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

View Proteome Sciences Profile